Cambodia Pharmaceuticals and Healthcare Report Q4 2012

Date: October 24, 2012
Pages: 57
US$ 1,295.00
Report type: Strategic Report
Delivery: E-mail Delivery (PDF), Download
ID: C426170E7AEEN

Download PDF Leaflet

Includes 3 FREE quarterly updates

BMI View:

Lacklustre efforts by the government to boost healthcare means that the Cambodia will be the least attractive to pharmaceutical investors as compared to its South East Asian peers as the population are unable to afford new treatments. Over the longer term we expect such trends to change and active participation in the Association of Southeast Asia Nations (ASEAN) Economic Community will boost its attractiveness.

Headline Expenditure Projections
  • Pharmaceuticals: KHR718bn (US$178mn) in 2011 to KHR806bn (US$193mn) in 2012; +12.2% in local currency terms and +8.8% in US dollar terms. Growth forecast unchanged from Q312, although we have adjusted the absolute value following reassessment of the market size.
  • Healthcare: KHR2,982bn (US$737mn) in 2011 to KHR3,312bn (US$794mn) in 2012; +11.1% in local currency terms and +7.8% in US dollar terms. Forecast unchanged from Q312.
  • Medical Devices: KHR108bn (US$27mn) in 2011 to KHR118bn (US$28mn) in 2011; +9.8% in local currency terms and +6.6% in US dollar terms. Forecast unchanged from Q312.
Risk/Reward Rating: Cambodia remains last out of the18 key markets in BMI’s Q412 Asia Pacific Pharmaceutical Risk/Reward Ratings with a score of 33.5, significantly lower than the regional average of 53.3. Near-term risks includes rampant corruption and poor healthcare provision although its membership in the ASEAN can boost its long-term attractiveness.

Key Trends And Developments
  • In August 2012, a Chinese medical delegation comprising seven traditional Chinese medical doctors will offer five free clinic services in two cities of Cambodia - Phnom Penh and Siem Reap. The free clinic services aim to help local patients through Chinese traditional treatments, said Zhou Xiaobao, the delegation head.
  • In July 2012, DKSH Healthcare and GlaxoSmithKline (GSK) have signed an agreement under which DKSH Healthcare will distribute GSK's pharmaceutical and vaccine products in Cambodia.
BMI Economic View:

Cambodia's high dollarisation rate, estimated to be 80%, should gradually fall over the coming years as market-friendly economic policies inspire more confidence in the domestic currency. This, in turn, should leave the economy less exposed to external shocks. BMI Political View; Cambodia's long-term political outlook largely depends on the ruling Cambodian People's Party (CPP)'s ability to address widespread corruption and income inequality, which have been fuelling public dissent against the government in recent years. Meanwhile, the lack of effective opposition to challenge the CPP at elections suggests that the party will continue to dominate the political scene over the coming years.
Executive Summary
SWOT Analysis
Cambodia Pharmaceuticals And Healthcare Industry SWOT
Pharmaceutical Risk/Reward Ratings
    Table: Asia Pacific Pharmaceutical Risk/Reward Ratings, Q412
Market Summary
Regulatory Regime
Intellectual Property Environment
Counterfeit Medicines
Pricing And Reimbursement
Industry Trends And Developments
Healthcare Sector
Health Insurance
Research & Development Sector
Clinical Trials
Medical Devices
Industry Forecast Scenario
Overall Market Forecast
    Table: Pharmaceutical Sales Indicators 2008-2016
Key Growth Factors – Industry
    Table: Healthcare Expenditure Indicators 2008-2016
    Table: Healthcare Governmental Indicators 2008-2016
    Table: Healthcare Private Indicators 2008-2016
Key Growth Drivers – Macroeconomic
    Table: Cambodia - Economic Activity, 2011-2016
Medical Device Market Forecast
    Table: Medical Devices Sales Indicators 2008-2016
Pharmaceutical Trade Forecast
    Table: Exports and Imports Indicators 2008-2016
Key Risks To BMI’s Forecast Scenario
Competitive Landscape
Pharmaceutical Industry
Pharmaceutical Company Developments
Pharmaceutical Wholesale
Pharmaceutical Retail
Company Profiles
Local Companies
PharmaProduct Manufacturing (PPM)
Cambodia Pharmaceutical Enterprise
Multinational Companies
Demographic Outlook
    Table: Cambodia's Population By Age Group, 1990-2020 ('000)
    Table: Cambodia's Population By Age Group, 1990-2020 (% of total)
    Table: Cambodia's Key Population Ratios, 1990-2020
    Table: Cambodia's Rural And Urban Population, 1990-2020
BMI Methodology
How We Generate Our Pharmaceutical Industry Forecasts
Pharmaceuticals Risk/Reward Ratings Methodology
Ratings Overview
    Table: Pharmaceutical Business Environment Indicators
    Table: Weighting Of Components
Skip to top

Cambodia Pharmaceuticals and Healthcare Report Q2 2012 US$ 1,295.00 Apr, 2012 · 55 pages
Cambodia Pharmaceuticals and Healthcare Report Q3 2012 US$ 1,295.00 Aug, 2012 · 56 pages
Thailand Pharmaceuticals and Healthcare Report Q3 2016 US$ 1,295.00 Jun, 2016 · 102 pages
Indonesia Pharmaceuticals and Healthcare Report Q3 2016 US$ 1,295.00 May, 2016 · 131 pages

Ask Your Question

Cambodia Pharmaceuticals and Healthcare Report Q4 2012
Company name*:
Contact person*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: